Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.50 and traded as high as $2.70. Microbot Medical shares last traded at $2.62, with a volume of 1,092,500 shares traded.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Microbot Medical in a research note on Thursday, April 10th.
Get Our Latest Analysis on Microbot Medical
Microbot Medical Price Performance
The stock has a market capitalization of $91.03 million, a price-to-earnings ratio of -3.27 and a beta of 1.40. The firm has a 50-day moving average of $1.76 and a 200 day moving average of $1.50.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, equities analysts forecast that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Investors Weigh In On Microbot Medical
An institutional investor recently raised its position in Microbot Medical stock. Geode Capital Management LLC boosted its holdings in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) by 7.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 142,659 shares of the biotechnology company's stock after buying an additional 10,442 shares during the quarter. Geode Capital Management LLC owned approximately 0.70% of Microbot Medical worth $160,000 at the end of the most recent reporting period. 16.30% of the stock is currently owned by institutional investors and hedge funds.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
